Medicina
Departamento
University of Florence
Florencia, ItaliaPublicaciones en colaboración con investigadores/as de University of Florence (113)
2024
-
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
2023
-
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research
Chest, Vol. 163, Núm. 3, pp. 586-598
-
EAACI guidelines on the diagnosis of IgE-mediated food allergy
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 12, pp. 3057-3076
-
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
European Journal of Cancer, Vol. 195
-
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
The Lancet, Vol. 401, Núm. 10373, pp. 269-280
-
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1605-1615
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
-
Three-year outcomes of A Randomized Multicentre Trial Comparing Revascularization and Optimal Medical Therapy for Chronic Total Coronary Occlusions (EuroCTO)
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 19, Núm. 7, pp. 571-579
2022
-
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities
European urology oncology, Vol. 5, Núm. 6, pp. 726-731
-
Contemporary treatment patterns and response in relapsed/refractory cutaneous T-cell lymphoma (CTCL) across five european countries
Cancers, Vol. 14, Núm. 1
-
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire
Annals of the rheumatic diseases, Vol. 81, Núm. 4, pp. 507-515
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362
-
TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice
Cardiology Journal, Vol. 29, Núm. 5, pp. 730-738
-
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456
2021
-
Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?
Current Urology Reports, Vol. 22, Núm. 11
-
Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia
Neurobiology of Aging, Vol. 99, pp. 99.e15-99.e22
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312